The many factors that influence 25(OH)D levels add complexity to questions about hypovitaminosis D
Advancing our knowledge of risk factors
Benefit/AFF risk ratio favors 3–5 years of treatment
A case study from Chad Deal, MD, illustrates how patients may present
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Puzzling constellation of findings lead to CT-guided bone biopsy
If denosumab is stopped, it should be replaced with another osteoporosis treatment
Dual-acting drug increases bone formation while decreasing resorption
Diagnosing an inherited metabolic bone disease later in life
Examining PT + HA for OA
Metabolic bone disease expert weighs evidence